Kevin McElwee - RepliCel Life Chief Scientific Officer
| REPCF Stock | USD 0 0.0001 5.26% |
Executive
Dr. Kevin McElwee, Ph.D., serves as Chief Scientific Officer of RepliCel Life Sciences Inc. Dr. McElwee is an Associate Professor in the Department of Dermatology and Skin Health at the University of British Columbia, and Director of the Hair Research Laboratory in the Vancouver Coastal Health Research Institute at Vancouver General Hospital . His research is funded by competitive grants awarded by multiple organizations including the Canadian Institute for Health Research . Dr. McElwee is one of only a small group of research scientists worldwide who studies hair biology and associated diseases. He has worked as a hair research scientist for 12 years and has published over 70 medical journal articles, research abstracts and academic book chapters on hair loss research since 2010.
| Age | 53 |
| Tenure | 15 years |
| Professional Marks | Ph.D |
| Phone | 604 248 8730 |
| Web | https://www.replicel.com |
RepliCel Life Management Efficiency
The company has return on total asset (ROA) of (1.651) % which means that it has lost $1.651 on every $100 spent on assets. This is way below average. RepliCel Life's management efficiency ratios could be used to measure how well RepliCel Life manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Michael LaBarre | Halozyme Therapeutics | 61 | |
| Kevin Eggan | Biomarin Pharmaceutical | N/A | |
| Pamela Murphy | Incyte | 74 | |
| Kristi Sarno | Ibio Inc | N/A | |
| Francesca Nolan | Sarepta Therapeutics | N/A | |
| Ben Strain | Incyte | N/A | |
| MA JD | Sutro Biopharma | N/A | |
| Sanjeev MD | ACADIA Pharmaceuticals | N/A | |
| Jennifer Johansson | Larimar Therapeutics | N/A | |
| Marc JD | Ibio Inc | N/A | |
| Janet Graesser | Vaxcyte | N/A | |
| Kimberly Manhard | ACADIA Pharmaceuticals | 64 | |
| Whitney Jones | Vaxcyte | N/A | |
| Evan Lippman | Alnylam Pharmaceuticals | N/A | |
| Steve Sabus | Syndax Pharmaceuticals | 57 | |
| Tolga MBA | Alnylam Pharmaceuticals | 52 | |
| Gregory MD | Tonix Pharmaceuticals Holding | 59 | |
| Evan MBA | Alnylam Pharmaceuticals | N/A | |
| Amy Fox | Halozyme Therapeutics | N/A | |
| Bob Mischler | ACADIA Pharmaceuticals | N/A | |
| Venkatesh Srinivasan | Sutro Biopharma | 63 | |
Management Performance
| Return On Asset | -1.65 |
RepliCel Life Sciences Leadership Team
Elected by the shareholders, the RepliCel Life's board of directors comprises two types of representatives: RepliCel Life inside directors who are chosen from within the company, and outside directors, selected externally and held independent of RepliCel. The board's role is to monitor RepliCel Life's management team and ensure that shareholders' interests are well served. RepliCel Life's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, RepliCel Life's outside directors are responsible for providing unbiased perspectives on the board's policies.
| BA CPA, Chief Officer | ||
| Kevin McElwee, Chief Scientific Officer | ||
| MSc PMP, Clinical Consultant | ||
| Ben Austring, Chief Mang | ||
| Andrew Schutte, CEO Pres | ||
| BEd LLB, Corp Director | ||
| Rolf MD, Chief Board |
RepliCel Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is RepliCel Life a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -1.65 | |||
| Operating Margin | (4.19) % | |||
| Current Valuation | 3.42 M | |||
| Shares Outstanding | 54.36 M | |||
| Shares Owned By Insiders | 68.42 % | |||
| Price To Earning | (1.00) X | |||
| Price To Sales | 8.35 X | |||
| Revenue | 353.74 K | |||
| Gross Profit | 353.74 K | |||
| EBITDA | (4.07 M) |
Currently Active Assets on Macroaxis
Other Information on Investing in RepliCel Pink Sheet
RepliCel Life financial ratios help investors to determine whether RepliCel Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in RepliCel with respect to the benefits of owning RepliCel Life security.